Phenobarbital Resurgence: A Renaissance in Modern Alcohol Withdrawal Treatment
Document Type
Article
Publication Date
10-2024
Publication Title
Chest Journal
Abstract
Alcohol withdrawal syndrome poses a significant burden on healthcare systems, impacting approximately 9% of the US population and resulting in substantial healthcare utilization costs, estimated at $30 billion. Within this context, Lincoln Hospital, a safety-net institution serving a socioeconomically disadvantaged population, contends with heightened rates of alcohol/substance use disorders and associated complications, exacerbating the strain on healthcare resources. This study aims to evaluate the efficacy of phenobarbital in reducing Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scores, impacting hospitalization rates, and assessing intensive care unit (ICU) utilization compared to conventional benzodiazepine therapy among patients admitted for alcohol withdrawal.
Volume
166
Issue
4
First Page
A2721
Last Page
A2722
Recommended Citation
Gora MI, Lim CY, Vohra A, Stukalau I, Ortega JM, Kwaylih RH et al Phenobarbital resurgence: a renaissance in modern alcohol withdrawal treatment. Chest. 2024 Oct;166(4):A2721-A2722. doi: 10.1016/j.chest.2024.06.1650.
DOI
10.1016/j.chest.2024.06.1650